Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals-Reference-Cited by-同舟云学术

Does Methodological Guidance Produce Consistency? A Review of Methodological Consistency in Breast Cancer Utility Value Measurement in NICE Single Technology Appraisals

Published:2017-07-05 Issue:2 Volume:2 Page:97-107
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Rose Micah^ORCID,Rice Stephen,Craig Dawn

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

http://link.springer.com/article/10.1007/s41669-017-0040-5/fulltext.html

Reference87 articles.

1. National Institute for Health and Care Excellence (NICE). Guide to the single technology appraisal process 2009. London: NICE; 2009.

2. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2004. London: NICE; 2004.

3. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2008. London: NICE; 2008.

4. National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal 2013. London: NICE; 2013.

5. Peasgood T, Ward SE, Brazier J. Health-state utility values in breast cancer. Expert Rev Pharmacoecon Outcomes Res. 2010;10(5):553–66.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of quality of data submitted for NICE technology appraisals over two decades;BMJ Open;2024-01

2. A Review of Economic Models Submitted to NICE’s Technology Appraisal Programme, for Treatments of T1DM & T2DM;Frontiers in Pharmacology;2022-05-11

3. Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers’ Information Sources;International Journal of Technology Assessment in Health Care;2022

4. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer;BMC Cancer;2021-11-18

5. Breast cancer STAs becoming more compliant with NICE methods;PharmacoEconomics & Outcomes News;2017-07